Exelixis Inc

Latest Exelixis Inc News and Updates

  • uploads///Graph
    Earnings Report

    The High Hope of Exelixis’s Cabometyx Label Expansion

    Exelixis (EXEL) plans to explore Cabometyx in combination with immune checkpoint inhibitors such as atezolizumab, ipilimumab, and nivolumab.

    By Margaret Patrick
  • uploads///Analysts recommendation
    Company & Industry Overviews

    What Amgen’s Analysts Recommend in August 2017

    Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”

    By Daniel Collins
  • uploads///AdobeStock_
    Earnings Report

    Exelixis Stock Rises on Revenue Beat

    Yesterday, Exelixis (EXEL) reported its second-quarter results after markets closed. Subsequently, its stock rose 0.99% and closed at $21.48.

    By Margaret Patrick
  • uploads///laboratory _
    Company & Industry Overviews

    Exelixis Stock Is Up despite Disappointing Clinical Trial Results

    While Exelixis was down 5.9% in after-hours trading after the announcement of disappointing clinical trial results, the stock recovered the losses and closed at $21.14 yesterday, 0.81% higher than its previous close. Based on this price performance, it seems that shareholders had already priced in the trial’s failure.

    By Margaret Patrick
  • uploads///virus _
    Company & Industry Overviews

    Sarepta Therapeutics Stock Rose 96% in 2018

    On January 4, Sarepta Therapeutics (SRPT) stock closed at $115.43, which represents ~8.21% growth from its prior close.

    By Daniel Collins
  • uploads///medic _
    Company & Industry Overviews

    Why Clovis Oncology Stock Rose 48% in November

    On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.

    By Daniel Collins
  • uploads///flasks _
    Company & Industry Overviews

    Why Exelixis Stock Soared 46% in November

    Exelixis stock has experienced solid growth over the last month after it hit its 52-week low of $13.42 on October 29.

    By Daniel Collins
  • uploads///achievement _
    Company & Industry Overviews

    Lenvima Is Expected to Boost Merck’s Oncology Portfolio in 2018

    Lenvima is expected to enable Merck to compete effectively with other oncology players such as Exelixis (EXEL) and Pfizer (PFE).

    By Margaret Patrick
  • uploads///FE
    Earnings Report

    How United Therapeutics Performed in 1Q18

    In 1Q18, United Therapeutics (UTHR) generated revenues of $389.2 million compared to $370.5 million in 1Q17.

    By Daniel Collins
  • uploads///Cabometyx
    Company & Industry Overviews

    Cabometyx Could Be Exelixis’s Long-Term Growth Driver

    In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx.

    By Daniel Collins
  • uploads///Sutent
    Company & Industry Overviews

    Pfizer’s Sutent Generated Higher Revenues in 4Q17

    In the US and international markets in 4Q17, Sutent generated revenues of $96 million and $180 million, respectively.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Inside Exelixis’s Label Expansion Collaborations for Cabozantinib

    As a part of the broader lifecycle management for Cabometyx, Exelixis is exploring the drug in combination with other immune checkpoint inhibitors.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Behind Exelixis’s Cabometyx Strategy for 2018

    Exelixis (EXEL) expects the FDA’s approval for Cabometyx for first-line RCC (renal cell carcinoma) to be a major revenue driver.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Reading the Expectations for Exelixis’s Net Profit Margin in 2017

    In 3Q17, Exelixis (EXEL) witnessed the rapid adoption of Cabometyx, mainly driven by the company’s promotional efforts focused on community oncologists.

    By Margaret Patrick
  • uploads///Cabometyx and Cometriq
    Company & Industry Overviews

    How Is Cabometyx and Cometriq Positioned after 1H17?

    In 2Q17, Exelixis’s (EXEL) Cabometyx generated revenues of ~$80.9 million compared to ~$17.6 million in 2Q16.

    By Daniel Collins
  • uploads///Sandostatin Afinitor and Exjade
    Company & Industry Overviews

    An Update on Novartis’s Sandostatin, Afinitor, and Exjade

    In 1H17, Novartis’s (NVS) Sandostatin generated revenues of around $789 million, which reflected a ~4% decline on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Chart  Opdivo
    Earnings Report

    Bristol-Myers Squibb’s 2Q17 Earnings: Opdivo

    Bristol-Myers Squibb’s (BMY) blockbuster drug Opdivo reported revenue of $1.2 billion in 2Q17, a 42% rise compared to $840 million in 2Q16.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Inside Exelixis’s Robust Growth Strategy for Cabometyx

    Exelixis is now developing a strong sales team to support the commercial launch of Cabometyx for indications like first-line RCC and second-line HCC.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Exelixis’s Tough Competition in Renal Cell Carcinoma

    After the launch of Cabometyx in the US in 2Q16, Exelixis has focused its attention on promoting it to thought leaders and clinicians who have treated many RCC patients.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Behind Exelixis’s Successful Commercial Launch of Cabometyx in 2016

    Launched in the US in 2Q16, Exelixis’s (EXEL) Cabometyx managed to fetch revenues of $31.2 million and $44.7 million in 3Q16 and 4Q16, respectively.

    By Margaret Patrick
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.